Recro Pharma, Inc. – Trademark Portfolio
Entity Type: 03
Recro Pharma, Inc. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 5 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include RECRO, ANJESO, SOCIETAL CDMO, and ANJESO (MELOXICAM) INJECTION. The owner is based in MALVERN, PA.
490 LAPP ROAD
MALVERN, PA 19355
Showing of trademarks Trademarks
Trademark Classifications
Recro Pharma, Inc.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Recro Pharma, Inc. have?
Recro Pharma, Inc. has 19 U.S. trademarks filed with the USPTO. Of these, 4 registered, 12 abandoned, 3 cancelled.
What trademark classes does Recro Pharma, Inc. file in?
Recro Pharma, Inc. files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 39 (Transportation & Storage), Class 40 (Treatment & Processing), Class 38 (Telecommunications). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Recro Pharma, Inc.'s most well-known trademarks?
Recro Pharma, Inc.'s registered trademark portfolio includes well-known marks such as RECRO, ANJESO, SOCIETAL CDMO, and ANJESO (MELOXICAM) INJECTION. These are among 4 currently registered trademarks in the portfolio.
What is Recro Pharma, Inc.'s trademark registration success rate?
Recro Pharma, Inc. has a 21% trademark registration rate, with 4 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.